About IO Biotech
We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform.
Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
We aim to disrupt the way cancer is treated with our approach, solidifying our product candidates as the cornerstones for multiple solid tumors.
Leadership
We have assembled a seasoned management team with extensive experience in developing novel oncology therapies, including advancing product candidates from preclinical research through to clinical development, and ultimately to regulatory approval.

Mai-Britt Zocca, Ph.D.
Member - President and Chief Executive Officer

Eva Ehrnrooth, M.D., Ph.D.
Chief Medical Officer

Muhammad Al-Hajj, Ph.D.
Chief Scientific Officer

Diane McDowell
SVP, Clinical Development and Medical Affairs

Dan Mannix
SVP, Regulatory Affairs

Margaret (Peggy) Siemon-Hryczyk
SVP, Clinical Operations
Board of Directors
Our board of directors has deep expertise in the fields of immuno-oncology, business and finance.

Peter Hirth, Ph.D.
Chairman

Kathleen Sereda Glaub, M.B.A.
Member

Christian Elling, Ph.D.
Member – Lundbeckfonden

Priyanka Belawat, Ph.D.
Member – HBM Healthcare Investments

Jack B. Nielsen, M. Sc.
Member - Vivo Capital

Vanessa Malier
Member – Kurma Partners

David V. Smith
Member

Mai-Britt Zocca, Ph.D.
Member - President and Chief Executive Officer